Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Apr;84(4):539-42.
doi: 10.4269/ajtmh.2011.10-0002.

Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults

Pouran Layegh  1 , Sara Rahsepar, Amir Ali Rahsepar
Affiliations
Clinical Trial

Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults

Pouran Layegh et al. Am J Trop Med Hyg. 2011 Apr.

Abstract

Some studies showed that children have a lower response to systemic use of pentavalent antimoniate than adults. We aimed to evaluate the response rate to Glucantime therapy in children and compare it with adults. One hundred and twelve patients with acute cutaneous leishmaniasis: (ACL) were divided into two equal groups of adults (> 15 yrs) and children (≤ 15 yrs). They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment. Per-protocol analysis showed a significantly lower response in the children group 20 and 45 days after initiation of the treatment (P = 0.0001, 95% confidence interval [CI] = 0.190 [0.079-0.456]/P = 0.0051, 95% CI = 0.317 [0.140-0.717], respectively). Moreover, after intention-to-treat analysis, the same results were seen in the younger group 20 and 45 days after treatment (P = 0.0003, 95% CI = 0.228 [0.098-0.528]/P = 0.0132, 95% CI = 0.382 [0.177-0.825], respectively). According to our results, systemic Glucantime has lower efficacy in treating ACL in children than adults.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The flow of participants through each stage of our study.
See this image and copyright information in PMC

References

    1. Talari SA, Talaei R, Shajari G, Vakili Z, Taghaviardakani A. Childhood cutaneous leishmaniasis: report of 117 cases from Iran. Korean J Parasitol. 2006;44:355–360. - PMC - PubMed
    1. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg. 2001;64:187–193. - PubMed
    1. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis. 2007;195:602–608. - PubMed
    1. Shahbazi F, Shahabi S, Kazemi B, Mohebali M, Abadi AR, Zare Z. Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. Parasitol Res. 2008;103:1159–1162. - PubMed
    1. Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, Kamesipour A. Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994–95. Bull World Health Organ. 1998;76:289–293. - PMC - PubMed

Publication types